Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies
Open accessThe DOI matches its Crossref record; 238 of the 239 references it cites were found in a registry or an index.
Abstract
Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer’s disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ɛ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“has been shown in a wide range of studies to contribute significantly to the pathogenesis and progression of AD2,8–19.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“leading to dysfunction and loss of synapses and eventual neuronal death1,2.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD pathology occurs well before (up to two decades) the onset of clinical symptoms2–4.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by an accumulation of senile plaques (SP) [composed mostly of fibrillary amyloid beta-peptide (Aβ) and dystrophic neurites] and neurofibrillary tangles (NFT) [composed of hyperphosphorylated tau protein] in the brain”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research from our laboratories11,12,34 and many others2,4,8,10 has shown that inefficient glucose utilization (and thus impaired ATP production) and oxidative damage are intimately related.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [2]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationThe precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 1×
“A peptides are hydrophobic 39–43 amino acid long products generated by the sequential proteolytic processing of the amyloid- protein precursor (A PP) [5, 6].”
BackgroundSelf-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 1×
“A peptides are hydrophobic 39–43 amino acid long products generated by the sequential proteolytic processing of the amyloid- protein precursor (A PP) [5, 6].”
BackgroundSelf-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Cited by
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Understanding mechanisms of antioxidant action in health and disease
Halliwell, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00645-4 · Cited by 629
“For example, vitamin E inhibits lipid peroxidation but may not prevent the increased oxidative DNA, RNA and protein damage seen in Alzheimer disease 123,156–159 .”
Zucchella, C., Sinforiani, E., Tamburin, S., Federico, A., Mantovani, E., Bernini, S., Casale, R., & Bartolo, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01058 · Cited by 297
Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics
Dhapola, R., Beura, S. K., Sharma, P., Singh, S. K., & HariKrishnaReddy, D. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09021-z · Cited by 252
Prevention of dementia in an ageing world: Evidence and biological rationale
Grande, G., Qiu, C., & Fratiglioni, L. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101045 · Cited by 229
Metabolic Dysregulation Contributes to the Progression of Alzheimer’s Disease
Yan, X., Hu, Y., Wang, B., Wang, S., & Zhang, X. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.530219 · Cited by 220
“In addition, reactive microglia and astrocytes and other pathological events also contribute to the dysfunction and deprivation of synapses and, ultimately, neuronal death (Martins et al., 2018).”
BackgroundGlial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 202
“Indeed, oxidative stress can be both a cause and a consequence of neuroinflammation [53].”
BackgroundApolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease
Butterfield, D. A., & Mattson, M. P. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104795 · Cited by 188
Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview
Varesi, A., Carrara, A., Pires, V. G., Floris, V., Pierella, E., Savioli, G., Prasad, S., Esposito, C., Ricevuti, G., Chirumbolo, S., et al. (2022) · Cells · doi:10.3390/cells11081367 · Cited by 139
“Up to now, lipid peroxidation and many oxidative-stress-related molecules have been detected as differentially expressed in AD brain, urine, and/or CSF compared to controls, such as 3-nitrotyrosine, 4-hydroxynonenal, and 8-hydroxy-2-deoxyguanosine [161,162].”
BackgroundAPOE-amyloid interaction: Therapeutic targets
Wisniewski, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 131
Indoles as essential mediators in the gut-brain axis. Their role in Alzheimer's disease
Pappolla, M. A., Perry, G. L., Fang, X., Zagorski, M. G., Sambamurti, K., & Pöeggeler, B. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105403 · Cited by 129
Verma, A., Shteinfer‐Kuzmine, A., Kamenetsky, N., Pittala, S., Paul, A., Crystal, E. N., Ouro, A., Caspi, V. C., Pandey, S. K., Monsonego, A., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00329-7 · Cited by 116
“Reactive microglia and astrocytes play a key role in neuroinflammation, and in AD, they contribute to the dysfunction and deprivation of synapses and to the neuronal death [117].”
Chatterjee, P., Fernando, M. G., Fernando, B., Dias, C. B., Shah, T. M., Silva, R., Williams, S., Pedrini, S., Hillebrandt, H., Goozee, K. G., et al. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111209 · Cited by 112
Self-citationA review of the application of deep learning in the detection of Alzheimer's disease
Gao, S., & Lima, D. (2021) · International Journal of Cognitive Computing in Engineering · doi:10.1016/j.ijcce.2021.12.002 · Cited by 122
Dhiman, K., Gupta, V. B., Villemagne, V. L., Eratne, D., Graham, P. L., Fowler, C., Bourgeat, P., Li, Q., Collins, S., Bush, A. I., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12005 · Cited by 93
Self-citationRole of Oxidative Stress and Metal Toxicity in the Progression of Alzheimer’s Disease
Birla, H., Minocha, T., Kumar, G., Misra, A., & Singh, S. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200122122512 · Cited by 95
“Oxidative stress is the perturbation between the production of both reactive oxygen species (ROS) and reactive nitrogen species (RNS) and antioxidant defense hence, responsible for the development of neurodegenerative disorders [2-12].”
BackgroundSarasamma, S., Audira, G., Juniardi, S., Sampurna, B. P., Liang, S., Hao, E., Lai, Y., & Hsiao, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103195 · Cited by 90
“Currently, there are more than 50 million people living with Alzheimer’s Disease (AD) in the world; this is greater than the total population of Spain and is projected to reach nearly 150 million by 2050 [1].”
BackgroundGu, X., Zhou, J., Zhou, Y., Wang, H., Si, N., Ren, W., Zhao, W., Fan, X., Gao, W., Wei, X., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00779-7 · Cited by 81
Park, J. S., Rehman, I. U., Choe, K., Ahmad, R., Lee, H. J., & Kim, M. O. (2023) · Nutrients · doi:10.3390/nu15133059 · Cited by 86
“Oxidative burden is caused by a homeostatic imbalance between the ROS and antioxidant defense mechanism, which has been shown to be involved in AD pathology [16].”
BackgroundRole of Hypoxia Inducible Factor-1α in Alzheimer’s Disease
Wang, Y., Huang, Z., Yuan, M., Feng, J., Cai, R.-L., Zou, Q., Pu, Y., Wang, S., Chen, F., Yi, W., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201448 · Cited by 81
Role of antioxidants and a nutrient rich diet in Alzheimer's disease
Veurink, G., Perry, G., & Singh, S. K. (2020) · Open Biology · doi:10.1098/rsob.200084 · Cited by 63
Magnetic Resonance Texture Analysis in Alzheimer's disease
Cai, J., He, Y., Zhong, X., Lei, H., Wang, F., Luo, G.-H., Zhao, H., & Liu, J.-C. (2020) · Academic Radiology · doi:10.1016/j.acra.2020.01.006 · Cited by 70
Synthesis of novel sulfonamides with anti‐Alzheimer and antioxidant capacities
Gök, N., Akıncıoğlu, A., Binici, E. E., Akıncıoğlu, H., Kılınç, N., & Göksu, S. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202000496 · Cited by 66
de Mendonça, L. J. C., & Ferrari, R. J. (2022) · Expert Systems with Applications · doi:10.1016/j.eswa.2022.118633 · Cited by 59
Song, Z., Xie, X., Chen, Y., Zhang, B., Li, X., Yang, Y., Mo, W., Zhang, J., & Xu, D. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.024 · Cited by 67
Kim, M., Kang, J., Lee, M., Han, J., Nam, G., Tak, E., Kim, M. S., Lee, H. J., Nam, E., Park, J., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13100 · Cited by 50
Bello-Medina, P. C., Hernández-Quiroz, F., Pérez-Morales, M., González-Franco, D. A., Cruz-Pauseno, G., García-Mena, J., Díaz-Cintra, S. Y., & Pacheco‐López, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.595583 · Cited by 50
Lu, H., Li, F., Wang, J., Zhao, F., Liu, C., Gao, Y., Liu, J., & Min, W. (2021) · Food & Function · doi:10.1039/d1fo01817e · Cited by 47
Nagarajan, I., & Priya, G. G. L. (2025) · Frontiers in Computer Science · doi:10.3389/fcomp.2024.1404494 · Cited by 56
From beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 53
Pereira, T. D. M. C., Côco, L. Z., Ton, A. M. M., Meyrelles, S. S., Campos‐Toimil, M., Campagnaro, B. P., & Vasquez, E. C. (2021) · Antioxidants · doi:10.3390/antiox10111845 · Cited by 71
Kommaddi, R. P., Tomar, D. S., Karunakaran, S., Bapat, D., Nanguneri, S., Ray, A., Schneider, B. L., Nair, D. K., & Ravindranath, V. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7754 · Cited by 44
“Increased production of reactive oxygen species (ROS) and reactive nitrogen species, and dysfunction of antioxidant enzymes have been shown in several studies to contribute significantly to AD pathogenesis (9, 10, 14, 37).”
Gut-brain axis and Alzheimer's disease: Therapeutic interventions and strategies
Singh, H., Chopra, C., Singh, H., Malgotra, V., Wani, A. K., Dhanjal, D. S., Sharma, I., Nepovimová, E., Alomar, S. Y., Singh, R., et al. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105915 · Cited by 43
Oka, T., Matsuzawa, Y., Tsuneyoshi, M., Nakamura, Y., Aoshima, K., Tsugawa, H., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-56837-1 · Cited by 44
Ophthalmic Biomarkers for Alzheimer’s Disease: A Review
Majeed, A., Marwick, B., Yu, H., Fadavi, H., & Tavakoli, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.720167 · Cited by 41
Non-invasive Biomarkers for Early Detection of Alzheimer’s Disease: a New-Age Perspective
Chimthanawala, N. M. A., Haria, A., & Sathaye, S. S. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03578-3 · Cited by 47
“Since the microtubule damage gives rise to a change in birefringence that is believed to occur before RNFL thinning, PS-OCT may be an effective tool to identify AD at an earlier stage [44].”
Oculomics: A Crusade Against the Four Horsemen of Chronic Disease
Patterson, E. J., Bounds, A. D., Wagner, S. K., Kadri-Langford, R., Taylor, R., & Daly, D. S. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-00942-x · Cited by 41
“Polarization-sensitive OCT has also been used to identify Alzheimer’s-associated birefringence (propagation and polarization of light) from microtubule damage [83].”
BackgroundEllagic Acid: A Dietary-Derived Phenolic Compound for Drug Discovery in Mild Cognitive Impairment
Wang, W., Wang, S., Liu, Y., Wang, X., Nie, J., Meng, X., & Zhang, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.925855 · Cited by 42
Bello-Medina, P. C., González-Franco, D. A., Vargas-Rodríguez, I., & Díaz-Cintra, S. Y. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2019.06.008 · Cited by 41
Multifaceted Alzheimer’s Disease: Building a Roadmap for Advancement of Novel Therapies
Kaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03415-w · Cited by 35
Retina Oculomics in Neurodegenerative Disease
Suh, A., Ong, J., Kamran, S. A., Waisberg, E., Paladugu, P., Zaman, N., Sarker, P., Tavakkoli, A., & Lee, A. G. (2023) · Annals of Biomedical Engineering · doi:10.1007/s10439-023-03365-0 · Cited by 36
Ashraf, A., Ashton, N. J., Chatterjee, P., Goozee, K. G., Shen, K., Fripp, J., Ames, D. J., Rowe, C. C., Masters, C. L., Villemagne, V. L., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00634-1 · Cited by 34
“Since AD represents a global disease burden, plasma proteins have been extensively associated with progression of the disease [35].”
BackgroundSelf-citationElder, M. K., Erdjument‐Bromage, H., Oliveira, M. M., Mamcarz, M., Neubert, T. A., & Klann, E. (2021) · Communications Biology · doi:10.1038/s42003-021-02324-6 · Cited by 40
Antioxidant, antimicrobial and neuroprotective effects of Octaviania asterosperma in vitro
Sevindik, М., Akgül, H., Selamoğlu, Z., & Braidy, N. (2020) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2020.1816584 · Cited by 33
“…in close proximity to key pathological hallmarks of AD, including extracellular amyloid-beta (Aβ) deposits, and intracellular neurofibrillary tangles containing hyperphosphorylated tau protein (Birnbaum et al. 2018; Butterfield and Boyd-Kimball 2018; Cheignon et al. 2018; Martins et al. 2018).”
BackgroundBello-Medina, P. C., Corona-Cervantes, K., Zavala-Torres, N. G., González, A., Pérez-Morales, M., González-Franco, D. A., Gómez, A., García-Mena, J., Díaz-Cintra, S. Y., & Pacheco‐López, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158209 · Cited by 35
“AD is a neurodegenerative disorder characterized by β-amyloid peptide (Aβ) plaques and tau neurofibrillary tangle formation [1,2] with progressive cognitive deficit [1,3].”
BackgroundQiu, F., Zhou, Y., Deng, Y., Yi, J., Gong, M., Liu, N., Wei, C., & Xiang, S. (2019) · Chemosphere · doi:10.1016/j.chemosphere.2019.125114 · Cited by 33
Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning
Castillo-Barnés, D., Su, L., Ramírez, J., Salas-Gonzalez, D., Martínez-Murcia, F. J., Illán, I. A., Segovia, F., Ortíz, A., Cruchaga, C., Farlow, M. R., et al. (2020) · Information Fusion · doi:10.1016/j.inffus.2020.01.001 · Cited by 32
“Findings obtained from DIAD can be extrapolated to the sporadic LOAD so it is expected that better treatments will be prescribed at pre-clinical stages of the disease when damage is minimal and pathogenesis can be slowed down or even prevented from progressing [7, 29, 30, 31, 24, 5].”
BackgroundInfluentialSelf-citationHuang, C., Rust, N. C., Wu, H., & Hart, G. W. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.354515 · Cited by 29
“…(AD) is a progressive neurodegenerative disease characterized by extracellular amyloid beta (Aβ) plaques, intracellular phosphorylated microtubule-associated tau protein tangles, and progressive cognitive decline involving memory loss and higher executive function deficits (Martins et al., 2018).”
He, J., Liu, F., Xu, T., Ma, J., Yu, H., Zhao, J., Xie, Y., Luo, L., Yang, Q., Lou, T., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115807 · Cited by 29
Chen, H., Sun, J., Fang, H., Lin, Y., Wu, H., Lin, D., Yang, Z., Zhou, Q., Zhao, B., Zhou, T., et al. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2400106 · Cited by 29
“Alzheimer ’ s disease (AD) is characterized by the accumulation of amyloid-β (A β ) peptides, dystro ‐ phic neurites, and neurofibrillary tangles (Martins et al., 2018), which are considered hallmarks of the disease.”
d-ribose and pathogenesis of Alzheimer’s disease
Javed, M., Ahmad, M. I., Javed, H., & Naseem, S. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05243-7 · Cited by 28
The Eye as a Diagnostic Tool for Alzheimer’s Disease
Hussain, A., Sheikh, Z., & Subramanian, M. L. (2023) · Life · doi:10.3390/life13030726 · Cited by 29
“Particularly, the hallmark pathological signs of AD, amyloid β-protein (Aβ), and neurofibrillary tangles (NFTs) of hyperphosphorylated (p)Tau protein have been identified in the retina [6,8].”
BackgroundHIF-1α serves as a co-linker between AD and T2DM
Yang, H. T., Ren, K., Zhang, Y., Yang, L., Cao, H., Yuan, X., Su, L., Li, H., Feng, X., & Liu, D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116158 · Cited by 29
CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort
Spallazzi, M., Barocco, F., Michelini, G., Immovilli, P., Taga, A., Morelli, N., Ruffini, L., & Caffarra, P. (2019) · Acta Neurologica Belgica · doi:10.1007/s13760-019-01112-8 · Cited by 29
Bello-Medina, P. C., González-Franco, D. A., Vargas-Rodríguez, I., & Díaz-Cintra, S. Y. (2019) · Neurología · doi:10.1016/j.nrl.2019.06.002 · Cited by 28
Abo‐Youssef, A. M., Khallaf, W. A. I., Khattab, M. M., & Messiha, B. A. S. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111441 · Cited by 27
Castañeda, A., Ferraz, R., Vieira, M., Cardoso, I., Vasconcelos, V. M., & Martins, R. F. (2021) · Marine Drugs · doi:10.3390/md19060343 · Cited by 29
“As early events on AD, chronic inflammation has been registered [40].”
BackgroundInfluentialSelf-citationStudy of mitophagy and ATP-related metabolomics based on β-amyloid levels in Alzheimer's disease
Xiong, X., Li, S., Han, T.-L., Zhou, F., Zhang, X., Tian, M., Tang, L. P., & Li, Y. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112266 · Cited by 26
Daré, L. R., Garcia, A., Soares, C. B., Lopes, L. F., das Neves, B.-H. S., Dias, D. V., & Mello‐Carpes, P. B. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.00152 · Cited by 26
Dimethyl fumarate does not mitigate cognitive decline and β-amyloidosis in female APPPS1 mice
Möhle, L., Brackhan, M., Bascuñana, P., & Pahnke, J. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147579 · Cited by 21
Li, J.-G., Chu, J., & Praticò, D. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0268-1 · Cited by 22
Tracing the Path between Mushrooms and Alzheimer’s Disease—A Literature Review
Silva, A. M., Preto, M., Grosso, C., Vieira, M., Delerue-Matos, C. M., Vasconcelos, V. M., Reis, M. A., Barros, L., & Martins, R. F. (2023) · Molecules · doi:10.3390/molecules28145614 · Cited by 25
“In fact, it was found that mushroom extracts and compounds were efficient against the main anti-AD-related mechanisms, including the inhibition of BACE1 [10,12], the inhibition of the Aβ aggregation, and the inhibition of AChE and butyrylcholinesterase (BChE) (Figure 1).”
BackgroundSelf-citationSymptoms and conventional treatments of Alzheimer's disease
Chorawala, M. R., Shah, A. C., Pandya, A. J., Kothari, N. R., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00009-1 · Cited by 21
Involvement of inflammasomes in the pathogenesis of Alzheimer's disease
Beder, N., Belkhelfa, M., & Leklou, H. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241283677 · Cited by 22
Takayama, K., Fujiwara, K., & Inoue, S. (2019) · Genes to Cells · doi:10.1111/gtc.12721 · Cited by 20
NOX2 in Alzheimer's and Parkinson's disease
Dustin, C. M., Shiva, S. S., Vazquez, A. L., Saeed, A., Pascoal, T. A., Cifuentes-Pagano, E., & Pagano, P. J. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103433 · Cited by 20
Athanasiou, E., Gargalionis, A. N., Anastassopoulou, C. G., Tsakris, A., & Boufidou, F. (2022) · Brain Sciences · doi:10.3390/brainsci12081010 · Cited by 20
“Numerous studies support that oxidative stress contributes to AD pathogenesis and progression [108,109], whereas different viruses are commonly associated with the presence of oxidative stress in infected cells [110,111].”
BackgroundFu, J., Song, W., Song, X., Li, F., Wang, X., Leng, Y., Wang, J., Liu, C., & Min, W. (2023) · Foods · doi:10.3390/foods12122329 · Cited by 20
“A global increase in the number of aging people has led to a surging incidence of neurodegenerative diseases, such as Alzheimer’s disease (AD) and vascular dementia, mainly characterized by the decline or loss of learning and memory capacity [1].”
BackgroundSomin, S., Kulasiri, D., & Samarasinghe, S. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00344-2 · Cited by 20
“HNE is a by-product of oxidative stress, which occurs as a result of lipid peroxidation [11, 221].”
BackgroundPinky, P., Neha, N., Ali, M., Tiwari, P., Alam, M. M., Hattiwale, H. M., Jamal, A., & Parvez, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102069 · Cited by 17
Madireddy, S., & Madireddy, S. (2019) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001026 · Cited by 16
“In particular, mitochondrial dysfunction is caused by a number of factors, including oxidative stress from the generation of ROS, membrane damage, mitochondrial damage (DNA-related), the destabilization of ionic gradients, and interactions with Aβ, which is regarded as a toxic protein [67,68].”
BackgroundLiu, Y., Xu, S., Bian, H., Qian, Y., Li, H., Shu, S., Chen, J., Cao, X., Gu, Y., Jin, J., et al. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.05.002 · Cited by 16
Alteration of Metabolic Profiles during the Progression of Alzheimer’s Disease
Yu, W., Chen, L., Li, X., Han, T.-L., Yang, Y., Hu, C., Yu, W., & Lü, Y. (2023) · Brain Sciences · doi:10.3390/brainsci13101459 · Cited by 18
“Moreover, other pathological events also contribute to the disease’s pathology, such as increased levels of reactive oxygen species, cytokine release, and the activation of microglia and astrocytes [7].”
BackgroundJahed, F. J., Rahbarghazi, R., Shafaei, H., Rezabakhsh, A., & Karimipour, M. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.04.014 · Cited by 16
Hu, Y.-R., Xing, S., Chen, C., Shen, D., & Chen, J.-L. (2019) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2019.09.002 · Cited by 15
Gao, L., Wang, B., Cui, X., Xia, L., Li, X., Núñez-Figueredo, Y., Li, D., Liu, K., Wang, H., & Jin, M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111334 · Cited by 16
Testosterone deficiency worsens mitochondrial dysfunction in APP/PS1 mice
Zhang, T., Chu, Y., Wang, Y., Wang, Y., Wang, J., Ji, X., Zhang, G., Shi, G., Cui, R., & Kang, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1390915 · Cited by 14
Wang, W., Long, P., He, M., Luo, T., Li, Y., Yang, L., Zhang, Y., & Wen, X. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176750 · Cited by 14
Abbas, S., Latif, M. S., Shafie, N. S., Ghazali, M. I., Abidin, N. A. Z., Mustafa, M. K., & Kormin, F. B. (2021) · Food Research · doi:10.26656/fr.2017.5(2).355 · Cited by 18
“Linked to AD, model mice experiments have shown high oxidative stress and increased deposition of Aβ in response to a defective antioxidant defense system (Tönnies and Trushina, 2017; Martins et al., 2018).”
MethodLaws, J. S., & Smid, S. D. (2023) · Current Research in Toxicology · doi:10.1016/j.crtox.2023.100144 · Cited by 12
“Oxidative stress is most notably caused by the production and accumulation of reactive oxygen species (ROS) and has been recognized as a key contributor to many neurodegenerative diseases, including Alzheimer ’ s disease (Martins et al., 2018).”
BackgroundPotential benefits of kefir and its compounds on Alzheimer's disease: A systematic review
Tanure, Y. C. B., Mafra, A. C. M., Guimarães, B. L. M., Magalhães, R. C., Fagúndez, C., do Nascimento, I. J. B., & Brito, J. C. M. (2025) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2025.100115 · Cited by 14
Wang, F., Xu, C., Chen, W., Duan, S., Xu, S., Dai, J., & Wang, Q. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210540 · Cited by 13
Geriatric medicine and health care for older people in Australia
Couteur, D. G. L., Flicker, L. A., & Hilmer, S. N. (2022) · Age and Ageing · doi:10.1093/ageing/afac001 · Cited by 12
Lizama, B. N., Keeling, E., Cho, E.-A., Malagise, E. M., Knezovich, N., Waybright, L., Watto, E., Look, G. C., Caro, V. D., Caggiano, A. O., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-87921-9 · Cited by 11
15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN
Daniels, A. J., McDade, E., Llibre‐Guerra, J. J., Xiong, C., Perrin, R. J., Ibáñez, L., Supnet‐Bell, C., Cruchaga, C., Goate, A., Renton, A. E., et al. (2026) · npj Dementia · doi:10.1038/s44400-025-00047-7 · Cited by 12
Self-citationNisa, N., Rasmita, B., Arati, C., Uditraj, C., Siddhartha, R., Dinata, R., Bhanushree, B., Bidanchi, R. M., Manikandan, B., Saeed, A.-L., et al. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-25943-4 · Cited by 12
Ferric–Tannic Nanoparticles Increase Neuronal Cellular Clearance
Phiwchai, I., Chariyarangsitham, W., Phatruengdet, T., & Pilapong, C. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00345 · Cited by 12
Tolstova, T. V., Dotsenko, E., Luzgina, N. G., & Rusanov, A. L. (2024) · Biomedicines · doi:10.3390/biomedicines12102243 · Cited by 12
“Key events in the pathogenesis of Alzheimer’s disease (AD) are associated with oxidative damage to neurons [67,68] and chronic microglial inflammation [67,69,70].”
BackgroundPinz, M. P., de Oliveira, R. L., da Fonseca, C. A. R., Voss, G. T., da Silva, B. P., Duarte, L. F. B., Domingues, W. B., Ortiz, H. G., Savall, A. S. P., Meotti, F. C., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03110-z · Cited by 11
“Increased oxidant production and oxidative damage have been implicated in the pathogenesis and progression of AD [59, 60].”
BackgroundGupta, U. C., & Gupta, S. C. (2019) · Current Nutrition & Food Science · doi:10.2174/1573401315666190801120306 · Cited by 10
Self-citationKaur, N., Kaur, S., Saini, M., Dhiman, M., & Mantha, A. K. (2020) · RASAYAN Journal of Chemistry · doi:10.31788/rjc.2020.1315596 · Cited by 9
Wasp Venom Ameliorates Scopolamine-Induced Learning and Memory Impairment in Mice
Chae, J. H., Oh, J., Lim, J. S., Jeong, Y. A., Yun, H. S., Jang, C. H., Kim, H. J., & Kim, J. (2022) · Toxins · doi:10.3390/toxins14040256 · Cited by 9
“In particular, hallmarks of AD include an accumulation of senile plaques mainly consisting of fibrillary Aβ peptide, dystrophic neurites, and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain, leading to dysfunction and loss of synapses and eventual neuronal death [27,28].”
BackgroundNeurodegeneration, Mitochondria, and Antibiotics
Suarez-Rivero, J. M., López‐Pérez, J., Muela‐Zarzuela, I., Pastor‐Maldonado, C. J., Cilleros-Holgado, P., Gómez-Fernández, D., Álvarez-Córdoba, M., Munuera-Cabeza, M., Talaverón-Rey, M., Povea-Cabello, S., et al. (2023) · Metabolites · doi:10.3390/metabo13030416 · Cited by 10
“β-amyloid (Aβ) deposition and abnormally phosphorylated Tau protein deposition are the main components of SP and NFTs, respectively [150].”
BackgroundAguilar-Pineda, J. A., Paco-Coralla, S. G., Febres-Molina, C., Gamero-Begazo, P. L., Shrivastava, P., Vera-López, K. J., Dávila-Del-Carpio, G., López-Casaperalta, P., Gómez, B., & Cardenas, C. L. L. (2022) · Biomolecules · doi:10.3390/biom12040499 · Cited by 8
Synthesis of Anti‐Alzheimer Molecules: Bridging Chemical Approaches to Pharmaceuticals
Abbas, H., Noor, F., Khalid, S., Ahmad, M., Rasool, N., Malik, A. I., & Imran, M. (2025) · ChemistrySelect · doi:10.1002/slct.202405965 · Cited by 7
Air pollution as a key risk factor for alzheimer’s disease: A comprehensive review
Zhu, X., Guo, C., Zhang, Y., & Wei, Y. (2025) · Environmental Technology & Innovation · doi:10.1016/j.eti.2025.104555 · Cited by 6
Overexpression of C9orf72 exacerbates Aβ25‑35‑induced oxidative stress and apoptosis in PC12 cells
Chen, J., Zhang, M., Bai, H., Shi, P., Du, M., Zhang, S., & Lou, J. (2022) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2022-007 · Cited by 6
Hata, S., Hu, A., Piao, Y., Nakaya, T., Taru, H., Morishima‐Kawashima, M., Murayama, S., Nishimura, M., & Suzuki, T. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz297 · Cited by 6
“It is the most common neurological disorder in the aged population, and it is estimated that ∼70% of patients with dementia have AD (1,2).”
Background
Metadata
- Authors
- Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., Hone, E., Pedrini, S., Lim, W. L., Martins, I., Frost, S., Gupta, S., O’Bryant, S., Rembach, A., Ames, D., Ellis, K., Fuller, S. J., Brown, B., Gardener, S. L., Fernando, B., Bharadwaj, P., Burnham, S., Laws, S. M., Barron, A. M., Goozee, K., Wahjoepramono, E. J., Asih, P. R., Doecke, J. D., Salvado, O., Bush, A. I., Rowe, C. C., Gandy, S. E., & Masters, C. L.
- Affiliations
- Edith Cowan University (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- University of Toronto (CA)
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
- Commonwealth Scientific and Industrial Research Organisation (AU)
- University of North Texas (US)
- The University of Melbourne (AU)
- Australian Alzheimer’s Research Foundation (AU)
- Murdoch University (AU)
- Nanyang Technological University (SG)
- The University of Western Australia (AU)
- UNSW Sydney (AU)
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Cooperative Research Centre for Mental Health (AU)
- Corresponding author
- Martins, Ralph N.
- ORCID
- Martins, Ralph N.
- Villemagne, Victor
- Sohrabi, Hamid R.
- Chatterjee, Pratishtha
- Shah, Tejal M.
- Verdile, Giuseppe
- Fraser, Paul
- Taddei, Kevin
- Gupta, Veer B.
- Hone, Eugene
- Pedrini, Steve
- Lim, Wei Ling
- Martins, Ian
- Frost, Shaun
- O’Bryant, Sid
- Ellis, Kathryn
- Brown, Belinda
- Gardener, Samantha L.
- Burnham, Samantha
- Laws, Simon M.
- Barron, Anna M.
- Goozee, Kathryn
- Wahjoepramono, Eka J.
- Asih, Prita R.
- Doecke, James D.
- Salvado, Olivier
- Bush, Ashley I.
- Rowe, Christopher C.
- Masters, Colin L.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-03-13
- Volume
- 62
- Issue
- 3
- Pages
- 965-992
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5870031
- OpenAlex
- W2794133158
- Cited by
- 129
- References
- 239
- Citations by year
- 2026: 1 · 2025: 14 · 2024: 15 · 2023: 18 · 2022: 18 · 2021: 24 · 2020: 23 · 2019: 13 · 2018: 3
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc)
- Murdoch University Research Portal (submittedVersion)
- Australasian Journal of Paramedicine (submittedVersion, cc-by-nc)
- Deakin Research Online (Deakin University) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Australia, Humans, Biomarkers, Oxidative Stress, Amyloidogenic Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.